Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides each representing strategically important niches with their own competitive dynamics
News provided by eMed May 05, 2025, 13:02 ET Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed, the leading Population Health technology platform in remote chronic care management and 24/7/365 live care, today announced an industry-changing collaboration with leading global professional services firm, Aon , to provide GLP-1 obesity management services for the company's U.S
Clean the vials rubber stopper with an alcohol pad
Detoxification is a nutrient-dense process, requiring vitamins, minerals, and amino acids